Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline Review, H2 2012

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2012', provides an overview of the Attention Deficit Hyperactivity Disorder (ADHD) therapeutic pipeline. This report provides information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD). 'Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Attention Deficit Hyperactivity Disorder (ADHD).
- A review of the Attention Deficit Hyperactivity Disorder (ADHD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Attention Deficit Hyperactivity Disorder (ADHD) pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Attention Deficit Hyperactivity Disorder (ADHD) pipeline depth and focus of Attention Deficit Hyperactivity Disorder (ADHD) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Attention Deficit Hyperactivity Disorder (ADHD) Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) 9
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics under Development by Companies 11
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Discovery and Pre-Clinical Stage Products 19
Comparative Analysis 19
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics – Products under Development by Companies 20
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics – Products under Investigation by Universities/Institutes 23
Companies Involved in Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Development 25
DURECT Corporation 25
Johnson & Johnson 26
Abbott Laboratories 27
AstraZeneca PLC 28
Eli Lilly and Company 29
Egalet a/s 30
Shire Plc 31
Collegium Pharmaceutical, Inc. 32
NeuroSearch A/S 33
Cortex Pharmaceuticals, Inc. 34
Chelsea Therapeutics, Inc. 35
Yuyu Pharma, Inc. 36
Theravance, Inc. 37
Suven Life Sciences Ltd. 38
Spectrum Pharmaceuticals, Inc. 39
Avanti Therapeutics 40
Curemark, LLC 41
Supernus Pharmaceuticals, Inc. 42
NextWave Pharmaceuticals, Inc. 43
PsychoGenics, Inc. 44
Intra-Cellular Therapies, Inc. 45
Targacept, Inc. 46
KemPharm, Inc. 47
Attention Deficit Hyperactivity Disorder (ADHD) – Therapeutics Assessment 48
Assessment by Monotherapy Products 48
Assessment by Combination Products 49
Assessment by Route of Administration 50
Assessment by Molecule Type 52
Drug Profiles 54
CX-1739 - Drug Profile 54
LY2216684 - Drug Profile 56
AZD1446 - Drug Profile 57
TC-5619 - Drug Profile 59
CX-1796 - Drug Profile 61
OPC-34712 - Drug Profile 62
OPC-34712 - Drug Profile 64
Northera - Drug Profile 66
KP106 - Drug Profile 68
ABT-894 - Drug Profile 70
EG-P119 - Drug Profile 72
NSD-761 - Drug Profile 73
Oradur ADHD - Drug Profile 74
Eltoprazine - Drug Profile 75
Droxidopa + Carbidopa - Drug Profile 76
Methylphenidate - Drug Profile 78
Methylphenidate ER - Drug Profile 79
Focalin - Drug Profile 80
Adderall XR - Drug Profile 81
SUVN-502 - Drug Profile 82
COL-171 - Drug Profile 84
ITI-002 - Drug Profile 85
Vyvanse - Drug Profile 86
Vyvanse - Drug Profile 88
SPN-812 - Drug Profile 90
Adderall XR + Focalin XR - Drug Profile 91
CM-4612 - Drug Profile 92
AZD5213 - Drug Profile 93
Betahistine Hydrochloride - Drug Profile 95
Methylphenidate - Drug Profile 96
Amantadine - Drug Profile 97
Methylphenidate + Carnitine - Drug Profile 98
Methylphenidate + Risperidone - Drug Profile 99
Duloxetine - Drug Profile 101
Atomoxetine - Drug Profile 102
Strattera - Drug Profile 103
NWP06 - Drug Profile 104
YY-162 - Drug Profile 105
ND0801 - Drug Profile 106
Metadoxine - Drug Profile 107
Methylphenidate - Drug Profile 109
SPI-339 - Drug Profile 110
CX-2007 - Drug Profile 111
CX-2076 - Drug Profile 112
Bupropion - Drug Profile 113
Buspirone - Drug Profile 114
NWP09 - Drug Profile 115
TD-9855 - Drug Profile 116
JNS001 - Drug Profile 117
PD2005 - Drug Profile 118
PD2007 - Drug Profile 119
PD9475 - Drug Profile 120
KP415 - Drug Profile 121
ADHD Amphetamine Bio-MD System + MPAR - Drug Profile 123
Amphetamine Bio-MD System - Drug Profile 124
AT-AD-437 - Drug Profile 125
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics – Drug Profile Updates 126
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics – Discontinued Products 150
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Dormant Products 151
Attention Deficit Hyperactivity Disorder (ADHD) – Product Development Milestones 156
Featured News & Press Releases 156
Appendix 167
Methodology 167
Coverage 167
Secondary Research 167
Primary Research 167
Expert Panel Validation 167
Contact Us 168
Disclaimer 168

List of Tables
Number of Products Under Development for Attention Deficit Hyperactivity Disorder (ADHD), H2 2012 13
Products under Development for Attention Deficit Hyperactivity Disorder (ADHD) – Comparative Analysis, H2 2012 14
Number of Products under Development by Companies, H2 2012 16
Number of Products under Development by Companies, H2 2012 (Contd..1) 17
Number of Products under Investigation by Universities/Institutes, H2 2012 19
Comparative Analysis by Late Stage Development, H2 2012 20
Comparative Analysis by Mid Clinical Stage Development, H2 2012 21
Comparative Analysis by Early Clinical Stage Development, H2 2012 22
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 23
Products under Development by Companies, H2 2012 24
Products under Development by Companies, H2 2012 (Contd..1) 25
Products under Development by Companies, H2 2012 (Contd..2) 26
Products under Investigation by Universities/Institutes, H2 2012 27
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 28
DURECT Corporation, H2 2012 29
Johnson & Johnson, H2 2012 30
Abbott Laboratories, H2 2012 31
AstraZeneca PLC, H2 2012 32
Eli Lilly and Company, H2 2012 33
Egalet a/s, H2 2012 34
Shire Plc, H2 2012 35
Collegium Pharmaceutical, Inc., H2 2012 36
NeuroSearch A/S, H2 2012 37
Cortex Pharmaceuticals, Inc., H2 2012 38
Chelsea Therapeutics, Inc., H2 2012 39
Yuyu Pharma, Inc., H2 2012 40
Theravance, Inc., H2 2012 41
Suven Life Sciences Ltd., H2 2012 42
Spectrum Pharmaceuticals, Inc., H2 2012 43
Avanti Therapeutics, H2 2012 44
Curemark, LLC, H2 2012 45
Supernus Pharmaceuticals, Inc., H2 2012 46
NextWave Pharmaceuticals, Inc., H2 2012 47
PsychoGenics, Inc., H2 2012 48
Intra-Cellular Therapies, Inc., H2 2012 49
Targacept, Inc., H2 2012 50
KemPharm, Inc., H2 2012 51
Assessment by Monotherapy Products, H2 2012 52
Assessment by Combination Products, H2 2012 53
Assessment by Stage and Route of Administration, H2 2012 55
Assessment by Stage and Molecule Type, H2 2012 57
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics – Drug Profile Updates 130
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics – Discontinued Products 154
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics – Dormant Products 155
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics – Dormant Products (Contd..1) 156
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics – Dormant Products (Contd..2) 157
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics – Dormant Products (Contd..3) 158
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics – Dormant Products (Contd..4) 159

List of Figures
Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), H2 2012 13
Products under Development for Attention Deficit Hyperactivity Disorder (ADHD) – Comparative Analysis, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 18
Late Stage Products, H2 2012 20
Mid Clinical Stage Products, H2 2012 21
Early Clinical Stage Products, H2 2012 22
Discovery and Pre-Clinical Stage Products, H2 2012 23
Assessment by Monotherapy Products, H2 2012 52
Assessment by Combination Products, H2 2012 53
Assessment by Route of Administration, H2 2012 54
Assessment by Stage and Route of Administration, H2 2012 55
Assessment by Molecule Type, H2 2012 56
Assessment by Stage and Molecule Type, H2 2012 57